(June 27, 2018)


Sponsored by

Webinar Description:

CYP2D6 copy number variation is a critical aspect of PGx testing. However, not all CYP2D6 alleles are functionally similar. Depending on ethnicity, up to 45% of the population possesses non-functional CYP2D6 “hybrid alleles” including *36, *13 and *68. Many copy number detection methods cannot detect these alleles, resulting in an incorrect gene copy number or incorrect drug metabolism rate determination.

This webinar will provide an overview of the prevalence of CYP2D6 hybrid alleles and the genetic characteristics that make their detection challenging. Comparison studies showing the performance of common CYP2D6 copy number detection methods and Agena’s newly released VeriDose™ CYP2D6 CNV Panel with hybrid allele detection capability will be shared.


Keith JacksonKeith Jackson, MS
Senior Marketing Manager, Clinical Genetics
Agena Bioscience

Keith Jackson, MS, Senior Marketing Manager, Clinical Genetics at Agena Bioscience, focuses on the development of clinical applications for the MassARRAY System. He graduated with degrees in Biotechnology, Molecular Biology, and Healthcare Management from James Madison University and Johns Hopkins University.

Robin EvertsRobin Everts, PhD
Staff Scientist, Scientific Affairs
Agena Bioscience

Dr. Robin Everts, Staff Scientist, Scientific Affairs at Agena Biosciences has developed genotyping, somatic mutation analysis and DNA methylation assays for over 100 applications including pharmacogenetics, clinical genetics and somatic mutation profiling. Dr. Everts is also a contributor to the CDC’s Genetic Testing Reference Materials Coordination Program (GeT-RM, Pharmacogenomics workgroup) for which he created and tested the ADME PGx Pro Panel as well as several CYP450 single gene panels (CYP2C9, CYP2C19, CYP2D6). Dr. Everts was trained as a molecular geneticist and he has published over 45 peer-reviewed articles in different fields including gene expression in immunology, developmental biology, pharmacogenetics, as well as gene mapping. Over the last five years Dr. Everts has focused primarily on improving and expanding the pharmacogenetics and clinical genetics capabilities of the MassARRAY Analyzer platform. Dr. Everts earned a BSc and MSc in Animal Sciences from Wageningen Agricultural University, The Netherlands and a PhD in Molecular Genetics from Utrecht University, The Netherlands.